Subscribe To
Galectin therapeutics to share five scientific presentations at the liver meeting™ 2023, hosted by the aasld
Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of belapectin on cardiac repolarization (QT interval) ...
November 3, 2023, 12:00 pm
Novo nordisk just consolidated its grip on yet another market. is it a buy?
Novo Nordisk just acquired a promising pharmaceutical asset for kidney disease. The candidate could also address ...
October 29, 2023, 9:30 am
Novo nordisk (nvo) to acquire hypertension drug for $1.3b
Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertensio...
October 17, 2023, 12:01 pm
: novo nordisk to buy hypertension treatment from for $1.3 billion from kbp biosciences
Novo Nordisk A/S NVODK:NOVO.B said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled ...
October 16, 2023, 11:11 am
Novo nordisk buys hypertension drug ocedurenone for $1.3 billion—expanding ozempic maker's arsenal
The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension....
October 16, 2023, 10:12 am
Novo nordisk buys hypertension drug in $1.3 billion deal
Novo Nordisk (NVO) agreed to buy ocedurenone, a drug that treats uncontrolled hypertension and has the ...
October 16, 2023, 9:50 am
Novo nordisk in $1.3 bln deal to buy hypertension drug
Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential applica...
October 16, 2023, 7:12 am
Novo nordisk to buy hypertension treatment from for $1.3 billion from kbp biosciences
Novo Nordisk A/S NVO, +1.96% NOVO.B, +0.08% said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled ...
October 16, 2023, 7:11 am
Mineralys therapeutics announces upcoming poster presentations at two scientific conferences in november 2023
Late-breaking poster presentation at ASN’s Kidney Week 2023 – – –Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13,...
October 13, 2023, 8:10 pm
Fda accepts merck's (mrk) filing for sotatercept in pah disease
The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial ...
October 2, 2023, 12:46 pm
Alnylam continues to deliver, but an upcoming fda meeting could create some volatility
Alnylam has an upcoming FDA advisory committee meeting on the company's application for Onpattro in ATTR-CM, and I see some risk of a negative committ...
September 9, 2023, 8:26 am
Alnylam's (alny) zilebesiran meets goals in mid-stage study
Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high ca...
September 8, 2023, 8:17 am
J&j (jnj) to end pulmonary hypertension study on opsumit
The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre...
September 7, 2023, 9:46 am
Gossamer bio to present results of torrey fri sub-study at the european respiratory society international congress 2023
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercializa...
September 7, 2023, 7:44 am
Alnylam hypertension drug meets main goal in mid-stage study
Alnylam Pharmaceuticals said on Thursday its experimental therapy for hypertension met the main goal in...
September 7, 2023, 7:15 am
J&j to pull the plug on hypertension drug study
Johnson & Johnson said on Wednesday it has decided to stop a late-stage study testing its experimental drug to treat a type of ...
September 6, 2023, 6:01 pm
Alnylam: zilebesiran deal with roche reveals a very long development timeline
Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Aln...
July 30, 2023, 9:05 am
Gossamer bio to hold conference call with pah experts to discuss prosera phase 3 design and interim torrey ole results
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercializa...
July 24, 2023, 4:16 pm
Alnylam (alny) to co-develop hypertension drug with roche
Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of ...
July 24, 2023, 2:35 pm
Roche enters partnership with alnylam for hypertension therapy
Swiss pharmaceutical group Roche said on Monday it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-com...
July 24, 2023, 1:18 am